José Alfredo Salinas-Casanova

Dr. José Alfredo Salinas-Casanova

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
GGGerardo Garcia-Rivas
Gerardo Garcia-Rivas
OLOmar Lozano
Omar Lozano
JBJudith Bernal-Ramírez
Judith Bernal-Ramírez
CSChristian Silva-Platas
Christian Silva-Platas
FSFelipe Salazar-Ramírez
Felipe Salazar-Ramírez
GTGuillermo Torre-Amione
Guillermo Torre-Amione
Heart failure (HF) is characterized by energy deprivation, calcium (Ca2+) handling alterations, and inflammation: effects associated with mitochondrial dysfunction. Cannabidiol previously prevented mitochondrial dysfunction. Thus, it may prevent HF progression. In mice with HF, subcutaneous cannabidiol attenuated cardiac fibrosis, hypertrophy, loss of ejection fraction, and inflammation; isolated cardiomyocytes preserved cell shortening, Ca2+ handling, mitochondrial function and redox balance. Hypertrophied ventricular cardiomyoblasts suggested cannabidiol-mediated effects through peroxisome proliferator-activated gamma receptors. Therefore, cannabidiol in HF limited cardiac hypertrophy and preserved contractile function by sustaining cardiomyocyte and mitochondrial function through redox balance maintenance, supporting cannabidiol role as a cardioprotective therapy in HF.

15 December 2021 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
MCMauricio Castillo-Perez
Mauricio Castillo-Perez
CJCarlos Jerjes-Sanchez
Carlos Jerjes-Sanchez
ACAlejandra Castro-Varela
Alejandra Castro-Varela
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
EVEduardo Vázquez-Garza
Eduardo Vázquez-Garza
JPJathniel Panneflek
Jathniel Panneflek
To our knowledge, the treatment, outcome, clinical presentation, risk stratification of patients with venous thromboembolism and COVID-19 have not been well characterized. We searched for systematic reviews, cohorts, case series, case reports, editor letters, and venous thromboembolism COVID-19 patients’ abstracts following PRISMA and PROSPERO statements. We analyzed therapeutic approaches and clinical outcomes of venous thromboembolism COVID-19 patients. Inclusion: COVID-19 patients with venous thromboembolism confirmed by an imaging method (venous doppler ultrasound, ventilation-perfusion lung scan, computed tomography pulmonary angiogram, pulmonary angiography). We assessed and reported the original Pulmonary Embolism Severity Index for each pulmonary embolism patient. In addition, we defined major bleedings according to the International Society of Thrombosis and Haemostasis criteria. We performed a systematic review from August 9 to August 30, 2020. We collected 1,535 papers from PubMed, Scopus, Web of Science, Wiley, and Opengrey. We extracted data from 89 studies that describe 143 patients. Unfractionated and low-molecular-weight heparin was used as parenteral anticoagulation in 85/143 (59%) cases. The Food and Drug Administration-approved alteplase regimen guided the advanced treatment in 39/143 (27%) patients. The mortality was high (21.6%, CI 95% 15.2-29.3). The incidence of major bleeding complications was 1 (0.9%) in the survival group and 1 (3.2%) in the death group. Pulmonary Embolism Severity Index was class I in 11.6% and II in 22.3% in survivors compared to 0% and 6.5% in non-survivors, respectively. Patients who experienced venous thromboembolism events at home were more likely to live than in-hospital events. We determined a high mortality incidence of pulmonary embolism and a low rate of bleeding. Unfractionated and low-molecular-weight heparin drove parenteral anticoagulation and alteplase the advanced treatment in both groups. The original Pulmonary Embolism Severity Index could be helpful in the risk stratification.

2 April 2023 in Angiology
Verified
Journal Article
Closed access
ACAlejandra Castro-Varela
Alejandra Castro-Varela
DMDaniela M Martinez-Magallanes
Daniela M Martinez-Magallanes
MRMaria Fernanda Reyes-Chavez
Maria Fernanda Reyes-Chavez
JGJose Manuel Gonzalez-Rayas
Jose Manuel Gonzalez-Rayas
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
CJCarlos Jerjes-Sanchez
Carlos Jerjes-Sanchez
Data on characteristics and outcomes of coronavirus (COVID)-19 patients complicated with arterial thrombosis (AT) are scarce. Therefore, we carried out a systematic review (PRISMA, PROSPERO statements; PubMed, Scopus, and Web of Science) to identify risk factors, clinical presentation, treatment, and outcomes. We included publications from December 2019 to October 2020. Groups: (a) ischemic stroke, (b) thrombotic storm, (c) peripheral vascular thrombosis, (d) myocardial infarction, and (e) left cardiac thrombus or in-transit thrombus (venous system thrombus floating or attaching to the right heart). We considered 131 studies. The most frequent cardiovascular risk factors were: hypertension, diabetes, and dyslipidemia. A high proportion presented with asymptomatic, mild, or moderate COVID-19 ( n = 91, 41.4%). We identified a high percentage of isolated ischemic stroke and thrombotic storm. Groups with higher mortality rate: intracardiac thrombus (1/2, 50.0%), thrombotic storm (18/49, 36.7%), and ischemic stroke (48/131, 36.6%). A small number received thromboprophylaxis. Most patients received antithrombotic treatment. The most frequent bleeding complication was intracranial hemorrhage, primarily with isolated stroke. Overall mortality was 33.6% (74/220). Despite a wide range of COVID-19 severity, a high proportion had AT as a complication of non-severe disease. AT can affect different vascular territories; mortality is associated with stroke, intensive care unit stay, and severe COVID-19.

7 July 2026 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
VJVicente Jimenez-Franco
Vicente Jimenez-Franco
JRJahir Rodriguez-Rivera
Jahir Rodriguez-Rivera
RQRenata Quevedo-Salazar
Renata Quevedo-Salazar
José Alfredo Salinas-CasanovaJosé Alfredo Salinas-Casanova
José Alfredo Salinas-Casanova
MFMonica Flores-Zertuche
Monica Flores-Zertuche
GTGuillermo Torre-Amione
Guillermo Torre-Amione

14 November 2024 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
José Alfredo Salinas-CasanovaJosé Alfredo Salinas-Casanova
José Alfredo Salinas-Casanova
VJVicente Alonso Jiménez‐Franco
Vicente Alonso Jiménez‐Franco
CJCarlos Jerjes‐Sanchez
Carlos Jerjes‐Sanchez
JQJuan Alberto Quintanilla‐Gutiérrez
Juan Alberto Quintanilla‐Gutiérrez
EPErasmo De La Pena-Almaguer
Erasmo De La Pena-Almaguer
GTGuillermo Torre‐Amione
Guillermo Torre‐Amione